20-22 January 2023
online

Registration is now closed

Team

Ekaterina Melnichikhina
Project Manager
Ekaterina is the CEO and co-founder of LongHack. She has a passion for innovation and tech and advocates for longevity and a healthy lifestyle.
Alex Dobrin
Strategy Advisor at VitaDAO
Entrepreneur, Growth Hacker, Investor, and Longevity advocate
Pritam Kumar Panda
Scientific Advisor
Despite the fact that Pritam is a great scientist with more than 40 papers under his belt, he is also a master of communication. He is responsible for the challenges and scientific advisory in LongHack.
Laurence Ion
Core Contributor at VitaDAO
Laurence is an entrepreneur, longevity advocate, and investor. With a software engineering/tech startups background, and a keen passion for the scientific method, he's helping translate science into startups, on a mission to bring aging under medical control.

WINNERS

January 2023

We are a goal-driven association of passionate individuals unified by a vision: rejuvenation of the extracellular matrix.

Learn more

AGen-iNET

iNET is the first tool coming from AGen. It is an end-to-end analysis software for RNASeq data focused on aging-related diseases, and a user interface opens this analysis to everyone. You load the data, we give you the biomarkers.

Learn more

AdStella Therapeutics

AdStellais a detection and prognosis software with the potential to greatly improve patient outcomes and reduce costs in the healthcare system.Using gene expression as biomarkers and machine learning to predict the muscle state after future events.

Learn more

GeneWeavers

GeneWeavers enables privacy-preserving analytics of 'Longevity Genetic Polymorphisms' on self-sovereign genomic data using Weavechain. Researchers will be able to chain compute-to-data with multi-party computation to perform a secure analysis of participants' genomics data without ever seeing that sensitive information.

Learn more

Back to challenges

AGen-iNET

iNET provides a user-friendly way to obtain new insights from RNASeq data, focusing on aging and age-related diseases. It is the first real end-to-end analysis software for RNA-Seq data. Other products in the market offer only partial solutions for this kind of analysis. The user-friendly interface allows non-specialists to run analyses that usually require highly specialized teams. iNET covers all the analysis processes of RNA-Seq data using cutting-edge technologies, validation checkpoints following every step, and annotations supported by several curated databases. This approach ensures reproducible, precise, and accurate results, which are encrypted to ensure patients' privacy. In addition, all the processes run inside secure and portable containers. Another key feature is the network analysis we developed; our novel algorithm integrates the expression and mutations obtained from the RNA-Seq data with a priori knowledge about aging and specific diseases. Our software provides a unique perspective to identify biomarkers and therapeutic targets. The final result is a ranked list of potential biomarkers and an interactive tool where the user can explore the network to gain insights about the condition of interest. All the genes are annotated according to their involvement in the disease along with information about FDA-approved drugs that target these genes. These characteristics make our tool an invaluable resource for both industry and clinical settings. Our potential customers span from small/medium pharma companies that cannot afford a team of bioinformaticians, clinicians who need a tool to guide personalized medicine decisions, and academics who do not have the time to learn bioinformatics and pipeline design. The beta version of iNET already includes Sarcopenia as an example of age-related disease, but due to the software's versatility, several age-related diseases will be added to our platform in the future. Importantly, we are working to identify potential collaborators to validate our results in-vivo and increase the credibility of our technology. Our business plan includes selling licenses to those who want to run the analysis locally, and subscriptions to allow those without access to appropriate computing infrastructures to obtain actionable biological insights from their data.

Final Presentation

Team
Jacopo Umberto Verga MSc (Team leader, full stack developer)
Bianca Pasat MSc (full stack developer)
Kevin Ryan MPharm, MSc (back-end developer)
Muhammad Zainul Arifin MSc (full stack developer)
Usama Zafar MSc (front-end developer)

VitaDAO Hackathon Challenges

Long, healthy lives are the ultimate goal of humanity. With all the data in the world and technology, it is crucial to build patient-centered solutions that help people live longer and healthier. And we're only just getting started!

VitaDAO hackathon powered by LongHack is a forum for innovators to present ideas and solutions for behavioral health and wellness. Studies have shown that people who engage in healthier behaviors and have access to the latest health solutions live longer, more productive lives. If you have an idea that can help improve patient care, we want to hear about it! Join us at VitaDAO Hackathon to discuss the future of healthcare.

Challenges

Our Experts & Mentors

Evelyne Bischof, MD

Professor of medicine, MPH, FEFIM
Internal medicine specialist

Learn more

Nir Barzilai, MD

Director, Institute for Aging Research at the Albert Einstein College of Medicine

Learn more

Valentin Angerer

Entrepreneur, Business & Project Consultant, Interim Manager

Learn more

More mentors

Evelyne Bischof, MD

Internal medicine:
Chief physician associate of internal medicine and oncology at University Hospital Renji of Jiaotong University, Shanghai
Emergency medicine physician at the Shanghai East International Medical Center

Longevity:
Longevity physician at Human Longevity Inc.
Healthy Longevity Medicine Society, Vice-president
Longevity Science Foundation, Head of the Visionary Board

Dr. Bischof is a specialist in Internal Medicine, Artificial Intelligence (AI), and digital health, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions. The research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. Dr. Bischof published over 100 peer-reviewed papers and is a frequent speaker at scientific and medical conferences in Asia and Europe. A long-term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc.

Evelyne Bischof spent a decade practicing medicine, lecturing at medical schools, and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital, and Shanghai East Hospital. Dr. Bischof sits on several scientific and advisory boards of biotech and longevity hubs. Currently also affiliated with the Centre of Healthy Aging, Universität Zürich, and prev. senior attending physician of internal medicine at the University Hospital Basel.

Swiss board certified as internal medicine specialist (FMH), trained in Europe, USA, and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Tongji University hospitals, Shanghai and University Hospitals of Zurich and Basel (Switzerland).